menu
    • menu
    [{"orgOrder":0,"company":"TaiRx","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bora Pharmaceuticals Partners with TaiRx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"Foslinanib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TaiRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiRx \/ TaiRx","highestDevelopmentStatusID":"8","companyTruncated":"TaiRx \/ TaiRx"}]

    Find Clinical Drug Pipeline Developments & Deals by TaiRx

    Menu

    TaiRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TaiRx

                            Taiwan arrow
                            Luxepack
                            Not Confirmed

                            TaiRx

                            Taiwan arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Bora Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bora Pharmaceuticals Partners with TaiRx

                            Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...

                            Brand Name : CVM-1118

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 27, 2022

                            Lead Product(s) : Foslinanib,Sorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Bora Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth